CD44 and breast cancer: Invasion and wound healing migration assays demonstrated that treatment with ASR490 significantly inhibited the invasive and migratory potential of both BCSCs and BC cells (Figures 7A, B), albeit ASR490’s effect was more profound on the BCSCs (ALDH+ and CD44+/CD22− than the BC (ALDH−) cells.